Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.

Hurley, Rachel M; McGehee, Cordelia D; Nesic, Ksenija; Correia, Cristina; Weiskittel, Taylor M; Kelly, Rebecca L; Venkatachalam, Annapoorna; Hou, Xiaonan; Pathoulas, Nicholas M; Meng, X Wei; Kondrashova, Olga; Radke, Marc R; Schneider, Paula A; Flatten, Karen S; Peterson, Kevin L; Becker, Marc A; Wong, Ee Ming; Southey, Melissa S; Dobrovic, Alexander; Lin, Kevin K; Harding, Thomas C; McNeish, Iain; Ross, Christian A; Wagner, Jill M; Wakefield, Matthew J; Scott, Clare L; Haluska, Paul; Wahner Hendrickson, Andrea E; Karnitz, Larry M; Swisher, Elizabeth M; Li, Hu; Weroha, S John; Kaufmann, Scott H

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.

Hurley, Rachel M; McGehee, Cordelia D; Nesic, Ksenija; Correia, Cristina; Weiskittel, Taylor M; Kelly, Rebecca L; Venkatachalam, Annapoorna; Hou, Xiaonan; Pathoulas, Nicholas M; Meng, X Wei; Kondrashova, Olga; Radke, Marc R; Schneider, Paula A; Flatten, Karen S; Peterson, Kevin L; Becker, Marc A; Wong, Ee Ming; Southey, Melissa S; Dobrovic, Alexander; Lin, Kevin K; Harding, Thomas C; McNeish, Iain; Ross, Christian A; Wagner, Jill M; Wakefield, Matthew J; Scott, Clare L; Haluska, Paul; Wahner Hendrickson, Andrea E; Karnitz, Larry M; Swisher, Elizabeth M; Li, Hu; Weroha, S John; Kaufmann, Scott H.

Afiliación

Hurley RM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
McGehee CD; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Nesic K; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Correia C; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Weiskittel TM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Kelly RL; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Venkatachalam A; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Hou X; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Pathoulas NM; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Meng XW; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Kondrashova O; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Radke MR; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA 98195, USA.
Schneider PA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Flatten KS; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Peterson KL; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Becker MA; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Wong EM; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria 3800, Australia.
Southey MS; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria 3800, Australia.
Dobrovic A; University of Melbourne Department of Surgery, Austin Hospital, Heidelberg, Victoria 3084, Australia.
Lin KK; Clovis Oncology, San Francisco, CA 94158, USA.
Harding TC; Clovis Oncology, San Francisco, CA 94158, USA.
McNeish I; Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, W12 0NN United Kingdom.
Ross CA; Division of Information Technology, Mayo Clinic, Rochester, MN 55905, USA.
Wagner JM; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Wakefield MJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Scott CL; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Haluska P; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Wahner Hendrickson AE; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Karnitz LM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Swisher EM; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA 98195, USA.
Li H; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Weroha SJ; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Kaufmann SH; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.

NAR Cancer ; 3(3): zcab028, 2021 Sep.

Article en En | MEDLINE | ID: mdl-34316715

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NAR Cancer Año: 2021 Tipo del documento: Article